# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.
Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.
Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study ...
Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.
Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate ...
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE:...
Wells Fargo analyst Tiago Fauth maintains Aerovate Therapeutics (NASDAQ:AVTE) with a Overweight and maintains $35 price target.
Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve ...